TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00830323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir + zanamivir
Description: oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir+ amantadine
Description: oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir
Description: oseltamivir (75mg bd for 5 days, oral)
Study: NCT02403518

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freedom Spinal Cord Stimulator System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freedom Spinal Cord Stimulator System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freedom Spinal Cord Stimulator System
Study: NCT03750864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-LCS Therapy
Description: All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance \& Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
Study: NCT02671188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% sodium chloride) will be used as placebo.
Study: NCT00322569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corio™ Pimecrolimus-Eluting Coronary Stent System
Description: Drug-eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
Description: Drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Costar ™ Paclitaxel-Eluting Coronary Stent System
Description: Drug-eluting Stent
Study: NCT02301338

Intervention type: OTHER
Intervention: Usual care

Intervention type: OTHER
Intervention: Usual care

Intervention type: OTHER
Intervention: Phone Calls
Study: NCT00887770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 12 x 50mg tablet, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 1 x 400mg capsule, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 12 x matched to AZD5672 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 x matched to AZD5672 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 3 x 50mg tablet, oral. single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 9 x matched to AZD5672 50mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 1 x matched to Moxifloxacin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 1 x matched to Moxifloxacin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 x matched to Moxifloxacin capsule
Study: NCT04496323

Intervention type: OTHER
Intervention: EE Golf
Description: Exercise in Golf and Playing 9 holes

Intervention type: OTHER
Intervention: EE Golf
Description: Exercise in Golf and Playing 9 holes
Study: NCT04197076

Intervention type: DRUG
Intervention: anti-PD-1 or anti-PD-L1
Description: immunotherapy anti-PD-1 or anti-PD-L1

Intervention type: DRUG
Intervention: EGFR-TKI, ALK inhibitor, ROS1 inhibitor
Description: targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor

Intervention type: DRUG
Intervention: investigator decided
Description: chemotherapy
Study: NCT00092053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: 50 mg tablets
Study: NCT01495351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888/Bortezomib
Description: ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
Study: NCT03990740

Intervention type: PROCEDURE
Intervention: Corneal sampling
Description: Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.

Intervention type: PROCEDURE
Intervention: Corneal sampling
Description: Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.
Study: NCT04510480

Intervention type: OTHER
Intervention: Observational study without specific intervention
Description: Observational study with standard cardiac arrest approach
Study: NCT02465918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motor cortex stimulation (Change of Stimulation Timing)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motor cortex stimulation (Change of Stimulation Timing)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motor cortex stimulation (Change of Stimulation Timing)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: motor cortex stimulation (Change of Stimulation Timing)
Study: NCT02406248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Description: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Study: NCT01777334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol 62.5/25 mcg
Description: Inhalation Powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg
Description: Inhalation Powder
Study: NCT02565433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
Study: NCT01436747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 2 micrograms daily, peroral, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 micrograms daily, peroral, 24 weeks
Study: NCT03322553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GERD-X
Description: Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GERD-X
Description: Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
Study: NCT04685447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded Hemodialysis for Covid19 maintenance hemodialysis patients
Description: After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients
Description: After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
Study: NCT02402322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled support
Description: Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-scheduled support
Description: Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
Study: NCT02833298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated reminders
Description: At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
Study: NCT04746885

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: DHA
Description: Oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: DHA
Description: Oral supplement
Study: NCT03763045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 25 mg: Phosphodiesterase inhibitor to be taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 50 mg: Phosphodiesterase inhibitor to be taken once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet.
Study: NCT02567305

Intervention type: OTHER
Intervention: Markers of NET formation
Description: i.e. Plasma DNA, Histone, MPO, DNase

Intervention type: OTHER
Intervention: Markers of NET formation
Description: i.e. Plasma DNA, Histone, MPO, DNase
Study: NCT02053883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin (BA-210)
Description: High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin (BA-210)
Description: High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
Study: NCT03219762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabpaclitaxel
Description: Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
Study: NCT01304498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: 9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL
Description: Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
Study: NCT01340001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the nucleus basalis of Meynert
Description: Differents parameters will be assessed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electrical stimulation of the nucleus basalis of Meynert
Description: Differents parameters will be assessed.
Study: NCT03804606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to MTM Pharmacist
Description: Patients will be referred for an encounter with a medication therapy management pharmacist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to MTM Pharmacist
Description: Patients will be referred for an encounter with a medication therapy management pharmacist.
Study: NCT01854307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum and SVV/PPV
Study: NCT03209947

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ulnar nerve Ultrasound
Description: No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach by measure of ulnar nerve surface
Study: NCT02627378

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Membrane Oxygenation
Description: Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Extracorporeal Membrane Oxygenation
Description: Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
Study: NCT01497106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (normal living)
Description: Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
Study: NCT04065126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Ten sessions (two hours each) with physical activity and psycho-educational components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief psycho-education
Description: Two brief lectures with psycho-educational components, soon after baseline assessment and in connection to follow-up assessment.
Study: NCT04338789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
Study: NCT01080300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended Release
Description: Gabapentin ER 1800mg daily

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Sugar pill
Study: NCT03035110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioural Therapy (DBT) based skills groups
Description: Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
Study: NCT01018108

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single Photon Emission Computed Tomography
Description: Undergo single photon emission computed tomographt imaging

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture Therapy
Description: Undergo acupuncture

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary study

Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative Study
Study: NCT01982409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine
Study: NCT03131947

Intervention type: OTHER
Intervention: HIV positive patients
Description: As above

Intervention type: OTHER
Intervention: HIV positive patients
Description: As above
Study: NCT04852913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen's Technique
Description: The thumb of the therapist was placed on the top of the targeted muscle (upper trapezius, levator scapulae, tight pectoralis and sternocleidomastoid, longissimus capitis, splenius capitis cervical multifidus). The skin was carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb was flattened in the medial direction, when this happened the muscle would plop or 15 respond in some way. Heating pad + TENS will be given The session lasted for 20 minutes 3sessions/week for 6th week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convention Physical Therapy
Description: Myofascial Release + Active Range of Motion Deep transverse friction was given for 10 minutes followed by myofascial stretching of muscle for 3 times, each holding for 90 seconds. Then myofascial release was given using ulnar border of both palms of the therapist.~Active range of motion exercises will be given 10 reps with 5 seconds hold. Heating pad + Transcutaneous Electrical Nerve Stimulator (TENS) will be given The session lasted for 20 minutes 3sessions/week for 6th week
Study: NCT02446613

Intervention type: OTHER
Group type: OTHER
Intervention: Pollen allergen extract
Description: Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
Study: NCT01808183

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy Pads
Description: NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
Study: NCT03463499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid and Chondroitin Sulfate
Description: Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
Study: NCT02601209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT04368845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: The treatment arm will be given up to 1-hour breathing exercises, aerobic and resistive training exercises administered by a physiotherapist via a telerehabilitation device every 10 days for a six-month period.
Study: NCT01857726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Transarterial chemoembolization (TACE) with adriamycin
Study: NCT03315494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 200 mg capsule with no inactive excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 200 mg capsule with no inactive excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 200 mg capsule with no inactive excipients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo 180 mg capsule filled with microcrystalline cellulose.
Study: NCT01857726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Transarterial chemoembolization (TACE) with adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: transarterial chemoinfusion with cisplatin 50-100 mg
Study: NCT02281162

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Draw

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Draw
Study: NCT01421745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural Competence Education module
Description: A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
Study: NCT04242407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMTS
Description: DMTS applied before surgery and worn for 96 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching patches that have no active drug applied before surgery and worn for 96 hours
Study: NCT00134758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: During 2 years :~* between 40 and 50 kg : 500 mg/day~* between 51 and 75 kg : 750 mg/day~* between 76 and 100 kg : 1000 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During 2 years :~* between 40 and 50 kg : 2 tabs/day~* between 51 and 75 kg : 3 tabs/day~* between 76 and 100 kg : 4 tabs/day